Evidence map›Paper›PMID 41164351›Full record

ArticleColombia medica (Cali, Colombia)

Adherence with hormonal therapy in women with breast cancer: a cross-sectional study in Medellin, Colombia.

Katerin Puerta Alzate, Camila Lema Calidonio, Mauricio Lema Medina, Paula Villa García

Erratum issuedAbstract read
In one paragraph

Article in Colombia medica (Cali, Colombia). The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Katerin Puerta AlzateClínica de Oncología Astorga Medellín Colombia.ORCID https://orcid.org/0009-0006-7957-8770
Camila Lema CalidonioClínica de Oncología Astorga Medellín Colombia.ORCID https://orcid.org/0000-0002-4382-6676
Mauricio Lema MedinaClínica de Oncología Astorga Medellín Colombia.ORCID https://orcid.org/0000-0001-9346-0361
Paula Villa GarcíaUniversidad CES Universidad CES Medellín Colombia.ORCID https://orcid.org/0009-0007-2629-5424

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although hormone therapy is a cornerstone in the treatment of breast cancer, low therapeutic adherence is commonly reported, and there is limited evidence on the predictors that contributes to improving adherence in this population. Objective: To identify factors associated with adherence to hormone therapy in women with breast cancer, in an oncology clinic in Medellín-Colombia (2019- 2023). Methods: Cross-sectional analytical study. Women >18 years old with hormone receptor-positive breast cancer who were undergoing hormone therapy were included. The MMAS-8 scale was used to measure and classify therapeutic adherence into three levels: low, medium, and high. Data was analyzed by multinomial logistic regression. Results: One hundred seventy-eight patients with a median age of 64.0 years were included. 50.0% were treated with tamoxifen. The prevalence of non-adherence was 48.9%. 70.2% had adverse effects of hormone therapy, and forgetfulness was the main reason for discontinuation (76.19%). Age was associated with therapeutic adherence, with older women being the most adherent (83.5%). Women with adverse effects, stage III-IV, low socioeconomic and educational level, and a lack of support network had lower therapeutic adherence. Conclusions: A high prevalence of moderate and low therapeutic adherence is demonstrated in younger women from lower socioeconomic and educational backgrounds. Preventive strategies are needed to mitigate factors that negatively influence therapeutic adherence.

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsMedication AdherenceAdultAgedAged, 80 and overAge FactorsAnastrozoleColombiaCross-Sectional StudiesEducational StatusFemaleHumansLetrozoleLow Socioeconomic StatusMiddle AgedAnastrozoleAntineoplastic Agents, HormonalLetrozoleTamoxifenadverse reactions.breast neoplasmsdrug-related side effectsmedication adherencetamoxifenTreatment adherence and compliance

Identifiers

PMID41164351
PMCPMC12560826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.